Favorable Reimbursement Policies is driving the Us Apheresis Service Market Research Report Market, Are Expected To Drive Market Expansion In The Near Future At A CAGR Of 8.47% During The Forecast Period 2024 To 2035

Market Research Future (MRFR) has published a cooked research report on the “Us Apheresis Service Market” that contains information from 2019 to 2035.

The Us Apheresis Service Market is estimated to register a CAGR of 8.47% during the forecast period of 2024 to 2035.

MRFR recognizes the following companies as the key players in the Us Apheresis Service Market— include VERSITI, Fresenius Medical Care Ag, VITALANT, Carter BLOODCARE, IMPACTLIFE, Mayo Foundation For Medical Education And Research (MFMER), New York Blood Center (NYBC), The American National Red Cross, BIOBRIDGE Global, San Diego Blood Bank And Among Others.

Market Highlights

The Us Apheresis Service Market is estimated to register a CAGR of 8.47% during the forecast period and is estimated to reach USD 1,832.77 Million by 2035.

The growing incidence of chronic diseases such as cardiovascular diseases, kidney disorders, autoimmune diseases, and diabetes in the United States is significantly driving the demand for apheresis services. Chronic diseases are not only becoming more common but also more complex, leading to an increased need for specialized treatments. For instance, according to a 2022 report from the CDC, approximately 805,000 people in the United States suffer from a heart attack each year. CAD is a major risk factor for heart attacks, highlighting the significant impact of heart-related conditions on the U.S. population. As per CDC 2022, about 5% of adults aged 20 and older (roughly 1 in 20 people) are affected by coronary artery disease (CAD), a condition where the arteries that supply blood to the heart become narrowed or blocked. According to the American Kidney Fund, Inc., there were 6,418 living donor transplants performed in the U.S. last year. 

Apheresis, particularly therapeutic apheresis, has emerged as an essential tool in managing these conditions. This procedure works by selectively removing certain components of blood—such as harmful antibodies, excess lipids, or cholesterol—that contribute to the progression of these diseases. For example, in autoimmune diseases like lupus or myasthenia gravis, apheresis helps remove pathogenic antibodies that attack healthy tissues, while in cardiovascular conditions, it can reduce elevated LDL cholesterol levels (a key contributor to plaque buildup) in patients unresponsive to statins. By targeting specific elements in the blood, apheresis offers a highly effective and precise treatment that is often more tailored than traditional medications.

As the prevalence of chronic diseases continues to rise, especially among the aging population, the demand for apheresis services has surged. Older individuals are particularly susceptible to these long-term illnesses, as their immune systems weaken and the body’s ability to regulate processes diminishes with age. Furthermore, the increase in patients seeking personalized and less invasive treatments has led healthcare providers to adopt apheresis more frequently, making it an integral part of modern disease management. Thus, the growing burden of chronic diseases, especially among the aging population, is not only driving demand but also shaping the future growth of the apheresis services market.

Access Full Report @ https://www.marketresearchfuture.com/reports/us-apheresis-market-17897

Segment Analysis

The Us Apheresis Service Market has been segmented based By Service Type, By Application, By End User.

Based on service type, the US Apheresis Service Market has been segmented into Donor/Automated Apheresis, Therapeutic Apheresis, and Stem Cell Collection and Processing. The Therapeutic Apheresis segment held the largest market share in 2024, and the Stem Cell Collection and Processing segment is the fastest-growing segment during the forecast period (2025 -2035).

The U.S. Apheresis Service Market, segmented by service type, includes Donor/Automated Apheresis, Therapeutic Apheresis, and Stem Cell Collection and Processing. In 2024, Therapeutic Apheresis dominated the market share, driven by its critical role in treating autoimmune and neurological disorders, as well as its increasing adoption in hospitals and specialty clinics. This segment's growth is further supported by rising prevalence of chronic diseases and advancements in apheresis technology. However, the fastest-growing segment over the forecast period (2025–2035) is expected to be Stem Cell Collection and Processing. This growth is attributed to increasing applications in regenerative medicine, rising demand for stem cell transplantation, and ongoing research in cell-based therapies. The segment is also benefitting from expanding clinical trials and growing awareness about stem cell banking. These trends highlight a dynamic shift in the market, with innovation and personalized medicine driving future demand.

Based on Application, the US Apheresis Service Market has been segmented into Neurological Disorders, Autoimmune Disorders, Hematologic Disorders, Oncology, Metabolic Toxicology Disorders, Infectious Diseases, Cardiovascular Disorders, and Others. The Hematologic Disorders segment held the largest market in 2024, and the Oncology segment is the fastest growing segment during the forecast period.

The U.S. Apheresis Service Market, based on application, is segmented into Neurological Disorders, Autoimmune Disorders, Hematologic Disorders, Oncology, Metabolic Toxicology Disorders, Infectious Diseases, Cardiovascular Disorders, and Others. In 2024, the Hematologic Disorders segment held the largest market share due to the high prevalence of blood-related conditions such as leukemia, lymphoma, and sickle cell disease that require apheresis as part of their treatment. The demand is also driven by increasing awareness and advancements in transfusion medicine. However, the Oncology segment is projected to be the fastest-growing during the 2025–2035 forecast period. This growth is fueled by the rising incidence of cancer, growing use of apheresis in cell therapy and immunotherapy, and expanding clinical research in oncology-focused treatments. The market dynamics reflect a growing reliance on apheresis as a supportive and therapeutic tool in both chronic and life-threatening disease management.

 Based on End User, the US Apheresis Service Market has been segmented into Hospitals, Blood Banks, Specialty Clinics, Research Laboratories, and Biotechnology Pharmaceutical Companies. The Blood Banks segment held the largest market in 2024 and the Research Laboratories segment is the fastest growing segment during the forecast period.

The U.S. Apheresis Service Market, segmented by end user, includes Hospitals, Blood Banks, Specialty Clinics, Research Laboratories, and Biotechnology Pharmaceutical Companies. In 2024, the Blood Banks segment accounted for the largest market share due to the high demand for blood component separation, donor apheresis procedures, and the growing need for safe and efficient blood supply management. Blood banks play a critical role in meeting the needs of patients requiring plasma, platelets, and other blood components. However, the Research Laboratories segment is projected to witness the fastest growth during the forecast period (2025–2035). This is driven by increased investments in biomedical research, advancements in cell therapy and gene therapy, and the growing use of apheresis in experimental treatments and clinical trials. The expanding focus on personalized medicine and innovation in therapeutic approaches is expected to accelerate demand for apheresis services within research environments.

Region Analysis

Based on region, the US Apheresis Service Market has been segmented into North, South, Midwest, and West. South accounted for the largest market share in 2024 and is anticipated to reach USD 757.67 million by 2035 and projected to grow at the highest CAGR of 9.63% during the forecast period.

The U.S. Apheresis Service Market, based on region, is segmented into North, South, Midwest, and West. In 2024, the South region held the largest market share and is expected to maintain its dominance through 2035. The market in the South is projected to reach USD 757.67 million by 2035, growing at the highest compound annual growth rate (CAGR) of 9.63% during the forecast period. This growth is driven by a high concentration of healthcare facilities, rising prevalence of chronic diseases, increasing adoption of advanced apheresis technologies, and supportive state-level healthcare initiatives. Additionally, the presence of major blood banks and research institutions further boosts demand for apheresis services in the region. The South’s growing population and expanding access to specialized treatments also contribute to its leading position and rapid market expansion within the U.S. apheresis services landscape.

Key Findings of the Study

• The Us Apheresis Service Market is expected to reach USD 1,832.77 Million by 2035, at a CAGR of 8.47% during the forecast period.


• The Rest of Asia Pacific Region accounted for the fastest growing in the market.


• Based on Application, the Cellulosic segment was attributed to holding the largest market in 2024.


• include VERSITI, Fresenius Medical Care Ag, VITALANT, Carter BLOODCARE, IMPACTLIFE, Mayo Foundation For Medical Education And Research (MFMER), New York Blood Center (NYBC), The American National Red Cross, BIOBRIDGE Global, San Diego Blood Bank And Among Others, are the key market players.